A5073722593- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Immunotherapy and Immune Responses
- Autoimmune Bullous Skin Diseases
- Transgenic Plants and Applications
- T-cell and B-cell Immunology
- Colorectal Cancer Treatments and Studies
- Psoriasis: Treatment and Pathogenesis
- Nail Diseases and Treatments
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Immunodeficiency and Autoimmune Disorders
- Pharmacological Effects of Natural Compounds
- Adrenal Hormones and Disorders
- Genetic and rare skin diseases.
- Pharmaceutical studies and practices
- Herpesvirus Infections and Treatments
- Skin Diseases and Diabetes
- Cancer and Skin Lesions
- Drug-Induced Adverse Reactions
Ludwig-Maximilians-Universität München
2016-2025
University Hospital Augsburg
2023-2025
University of Lübeck
2024-2025
Universitair Ziekenhuis Brussel
2022-2024
Vrije Universiteit Brussel
2022-2024
LMU Klinikum
2012-2024
University Hospital Schleswig-Holstein
2024
University of Augsburg
2024
Gold Skin Care Center
2024
Saint Louis University
2023
Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of and interleukin-13, type 2 cytokines that may be important drivers atopic or allergic diseases such as dermatitis.
Abstract This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines well patients. It is consensus‐based guideline, taking available evidence other guidelines, systematic reviews and published studies into account. first part of the covers methods, patient perspective, general measures avoidance strategies, basic emollient treatment bathing, dietary intervention, topical anti‐inflammatory therapy, phototherapy antipruritic...
Abstract The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal Guidelines Research and Evaluation. consensus process consisted a nominal group DELPHI procedure. Management AE must consider individual symptomatic variability disease. Basic therapy focused on hydrating topical treatment, avoidance specific unspecific provocation factors. Anti‐inflammatory based glucocorticosteroids calcineurin inhibitors (TCI) used...
Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess efficacy safety nemolizumab (CIM331), humanized antibody against interleukin-31 receptor A, treatment dermatitis.In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe that was inadequately controlled by topical treatments receive subcutaneous (at dose 0.1 mg, 0.5 or 2.0 mg per kilogram body weight) placebo...
It has been suggested that epidermal Langerhans cells (LC) bearing immunoglobulin E (IgE) may be involved in the genesis of atopic disease. The identity IgE receptor(s) on LC remained unclear, although it represents a crucial point understanding cellular events linked to binding allergens via IgE. In this report, we demonstrate express high affinity receptor for Fc fragment (Fc epsilon RI) which has, so far, only described mast and basophils. Epidermal react with antibodies specific alpha...
Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, key cytokine driving peripheral inflammation in atopic dermatitis (AD). In phase II studies, tralokinumab combined with topical corticosteroids provided early and sustained improvements AD signs symptoms. Objectives To evaluate the efficacy safety of monotherapy adults moderate-to-severe who had an inadequate response to treatments. Methods two 52-week, randomized, double-blind,...
Abstract Atopic dermatitis ( AD ) is a clinically defined, highly pruritic, chronic inflammatory skin disease of children and adults. The diagnosis made using evaluated clinical criteria. Disease activity best measured with composite score assessing both objective signs subjective symptoms, such as SCORAD . management must consider the pathogenic variabilities also target flare prevention. Basic therapy includes hydrating topical treatment, well avoidance specific unspecific provocation...
Abstract Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis made using evaluated clinical criteria. Disease activity and burden are best measured with composite score, assessing both objective subjective symptoms, such as SCORing Dermatitis (SCORAD). AD management must take into account pathogenic variabilities, the patient’s age also target flare prevention. Basic therapy includes hydrating barrier‐stabilizing topical treatment universally applied,...
Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in U.S.A. patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use medicines, Japan whose AD existing therapies, Europe are candidates systemic therapy maintenance treatment of asthma their current medicines. trials have reported increased incidence conjunctivitis dupilumab vs. placebo. To characterize further...
IL-13 has an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human mAb that potently and specifically neutralizes IL-13.We sought to evaluate the efficacy safety of tralokinumab adults with moderate-to-severe AD.In this phase 2b study (NCT02347176), 204 were randomized 1:1:1:1 receive 45, 150, or 300 mg subcutaneous tralokinumab, placebo, every 2 weeks for 12 concomitant topical glucocorticoids. Coprimary end points change from baseline Eczema Area Severity...
Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with concomitant topical corticosteroids. Objectives To evaluate the efficacy safety of baricitinib patients moderate-to-severe AD who had inadequate response to therapies. Methods In two independent, multicentre, double-blind, III monotherapy trials, BREEZE-AD1 BREEZE-AD2, adults were randomized : once-daily placebo, mg, or 4 mg for 16 weeks....
Children with severe atopic dermatitis (AD) have limited treatment options.We report the efficacy and safety of dupilumab + topical corticosteroids (TCS) in children aged 6-11 years AD inadequately controlled therapies.In this double-blind, 16-week, phase 3 trial (NCT03345914), 367 patients were randomized 1:1:1 to 300 mg every 4 weeks (300 q4w), a weight-based regimen 2 (100 q2w, baseline weight <30 kg; 200 ≥30 kg), or placebo; concomitant medium-potency TCS.Both q4w q2w TCS regimens...
We analysed incidence, predictors, histological features and specific treatment options of anti-tumour necrosis factor α (TNF-α) antibody-induced psoriasiform skin lesions in patients with inflammatory bowel diseases (IBD).Patients IBD were prospectively screened for anti-TNF-induced lesions. Patients genotyped IL23R IL12B variants. Skin examined infiltrating Th1 Th17 cells. severe treated the anti-interleukin (IL)-12/IL-23 p40 antibody ustekinumab.Among 434 anti-TNF-treated IBD, 21 (4.8%)...
Abstract The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline Consensus Statement Development Manual. Four consensus conferences were held between December 2020 July 2021. Twenty‐nine experts (including clinicians patient representatives) from 12 European countries participated. This first part of includes general information its scope purpose, health questions covered, target users a methods section. It also provides...
To cite this article: Stalder J-F, Barbarot S, Wollenberg A, Holm EA, De Raeve L, Seidenari Oranje Deleuran M, Cambazard F, Svensson Simon D, Benfeldt E, Reunala T, Mazereeuv J, Boralevi Kunz B, Misery Mortz CG, Darsow U, Gelmetti C, Diepgen Ring Moehrenschlager Gieler Taïeb for the PO-SCORAD Investigators Group. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated Europe. Allergy 2011; 66: 1114–1121. Abstract Background: Patient-oriented medicine...
Prurigo nodularis is a chronic pruritic skin disease with multiple nodular lesions. Nemolizumab monoclonal antibody targeting the interleukin-31 receptor, which involved in pathogenesis of prurigo nodularis.
The epidermal growth factor receptor (EGFR) plays an important role in tissue homeostasis and tumor progression. However, cancer patients treated with EGFR inhibitors (EGFRIs) frequently develop acneiform skin toxicities, which are a strong predictor of patient's treatment response. We show that the early inflammatory infiltrate rash induced by EGFRI is dominated dendritic cells, macrophages, granulocytes, mast T cells. EGFRIs induce expression chemokines (CCL2, CCL5, CCL27, CXCL14)...